Furthermore, single-cell RNA sequencing analyses unequivocally confirmed MZT2B’s predominant enrichment within malignant epithelial cells, particularly in proliferating carcinoma subsets, and its consistent presence across primary LUAD tumors and various metastatic sites, suggesting its involvement throughout disease progression. This evidence concerns the gene MZT2B and carcinoma.